Pricing, Reimbursement & Market Access Webinars - Pharmaceutical and Biotech industries

CAR-T therapy: the future begins to take shape

High expectations have been built up around the pricing, reimbursement, and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies based on the novel mechanism of action and trial results that indicate curative potential for a large segment of the treatable population. However, CAR-T represents an entirely new way of delivering cancer therapy, with significant challenges for manufacturers and healthcare systems.

This eBook provides:
  • overviews of pricing and reimbursement of CAR‐T in France, Germany, and the UK
  • a summary of five key issues that are emerging from early regulatory, pricing, and reimbursement decisions
  • five strategies for success that manufacturers could consider.
ebook

info@prmaconsulting.com
UK (HQ) +44 (0)1252 786284
US +1 (415) 655 6798

Company registration number: 05893400

Follow us


Terms and conditions
Privacy statement
Cookie policy